Taken together, this study reveals the critical role of FTO in facilitating colon carcinoma by increasing PD-L1 expression, and therefore targeting FTO by means of either selective FTO inhibitor [125] or CRISPR/Cas9-based methods could hold the potential to control colon cancer in combination with anti-PD-L1 therapeutics (Table 1) [12]. The gene discussed is CD274; the disease is colon carcinoma.